文献速递放疗物理与技术姑息放疗与转移瘤

意大利红区新冠疫情期间放射肿瘤科两个月经验:薄冰上铺就安全之路

Two months of radiation oncology in the heart of Italian "red zone" during COVID-19 pandemic: paving a safe path over thin ice.
PubMed 文献 · Radiat Oncol · 2020-08-10

该研究回顾性分析了意大利伦巴第红区某放射肿瘤科在2020年2月24日至4月24日期间402例接受积极治疗的癌症患者数据。通过专项措施,放疗工作量仅下降17%,患者新冠感染率为3.23%(13/402),死亡率为1.24%(5/402),仅2.5%的进行中治疗因疑似或确诊新冠而暂停。结论支持在严格预防措施下疫情期间继续抗肿瘤治疗可行且安全。

要点

  • 放疗工作量仅下降17%,全身治疗和随访评估数量保持稳定。
  • 患者新冠感染率3.23%,死亡率1.24%,多数病例在3月24日前检出。
  • 仅2.5%的进行中治疗因新冠暂停,46.2%阳性患者未中断放疗。

核心结论

  • 尽管新冠癌症患者死亡率较高,但通过一致的预防措施,在SARS-Cov-2大流行期间继续抗肿瘤治疗具有可行性和安全性。

研究设计与样本

  • 回顾性分析2020年2月24日至4月24日意大利伦巴第红区某放射肿瘤科402例接受积极治疗的癌症患者数据,并分析科室运行指标。

主要发现

  • 放疗治疗次数下降17%,全身治疗给药和随访评估数量保持稳定,新治疗计划面临大幅下降。
  • 患者感染率为3.23%(13/402),死亡率为1.24%(5/402)。
  • 新冠患者中位年龄69.7岁,大多数为男性和吸烟者(84.6%),肺癌最常见(61.5%),84.6%为III-IV期,92.3%有合并症。
  • 92.3%的病例在3月24日前检出,仅2.5%的进行中治疗因疑似或确诊新冠而暂停,46.2%的阳性患者未中断放疗继续治疗。
  • 仅最后一个月,接受治疗患者感染率降至0.43%(1/232),工作人员中未报告新发感染。

临床怎么用

  • 在疫情高峰期通过专项预防措施可维持放射肿瘤科大部分工作负载,支持继续抗肿瘤治疗。

局限性

  • 本文为单中心回顾性分析,未报告其他局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Coronavirus Disease 2019 (COVID-19) pandemic had an overwhelming impact on healthcare worldwide. Outstandingly, the aftermath on neoplastic patients is still largely unknown, and only isolated cases of COVID-19 during radiotherapy have been published. We will report the two-months experience of our Department, set in Lombardy "red-zone". METHODS: Data of 402 cancer patients undergoing active treatment from February 24 to April 24, 2020 were retrospectively reviewed; several indicators of the Department functioning were also analyzed. RESULTS: Dedicated measures allowed an overall limited reduction of the workload. Decrease of radiotherapy treatment number reached 17%, while the number of administration of systemic treatment and follow up evaluations kept constant. Conversely, new treatment planning faced substantial decline. Considering the patients, infection rate was 3.23% (13/402) and mortality 1.24% (5/402). Median age of COVID-19 patients was 69.7 years, the large majority were male and smokers (84.6%); lung cancer was the most common tumor type (61.5%), 84.6% of subjects were stage III-IV and 92.3% had comorbidities. Remarkably, 92.3% of the cases were detected before March 24. Globally, only 2.5% of ongoing treatments were suspended due to suspect or confirmed COVID-19 and 46.2% of positive patients carried on radiotherapy without interruption. Considering only the last month, infection rate among patients undergoing treatment precipitated to 0.43% (1/232) and no new contagions were reported within our staff. CONCLUSIONS: Although mortality rate in COVID-19 cancer patients is elevated, our results support the feasibility and safety of continuing anticancer treatment during SARS-Cov-2 pandemic by endorsing consistent preventive measures.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Buglione M, Spiazzi L, Guerini AE, et al. Two months of radiation oncology in the heart of Italian "red zone" during COVID-19 pandemic: paving a safe path over thin ice. Radiat Oncol. 2020. PMID: 32778174. doi:10.1186/s13014-020-01631-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。